ClinicalTrials.gg
Status unknownNCT04766151NURSE-TTSUpdated Feb 23, 2021

Nitrate Use to Obtain Radial Spasm Embarrassment (NURSE - TTS Trial)

A Phase 3 interventional study of Transdermal glyceryl trinitrate 10mg patches and Placebo patches in Radial Artery Spasm, sponsored by 424 General Military Hospital. Status unknown at 1 site in Greece. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-02-23.

Sponsored by 424 General Military Hospital · Phase 3, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Transradial cardiac catheterization and percutaneous coronary intervention are increasingly being performed worldwide in elective and emergency procedures, with many centres adopting the transradial route as their first choice of arterial access. One of the most common complications encountered during transradial procedures is radial artery spasm. The aim of this study is to evaluate the Efficacy and Safety of the use of transdermal Glyceryl trinitrate patches applied to skin before cardiac catheterization to prevent the occurrence of radial artery spasm during transradial access cardiac catheterization.

02

Conditions studied

  • Radial Artery Spasm

Browse trials for

03

In context

Spasm

123 studies on the registry are indexed under Spasm; 7 are open to participants now.

This study's planned enrollment of 150 is above the median of 80 across 104 interventional studies indexed under Spasm.

Browse Spasm studies →

Lead sponsor

424 General Military Hospital is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 -85 years old who has been admitted for scheduled coronary angiography by radial artery

Exclusion criteria

Exclusion Criteria:

  • Prior same radial artery catheterization
  • Positive Allen test
  • Severe Hypotension (SBP\<100 mmHg)
  • Pregnancy
  • Ongoing Acute Myocardial Infarction
  • Ongoing cardiogenic shock
  • Known History of Nitrates intolerance/allergy
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Transdermal glyceryl trinitrate patches

    Drug: Transdermal glyceryl trinitrate 10mg patches

  • Placebo comparator
    Transdermal placebo patches

    Drug: Placebo patches

Interventions

  • DrugNitroglycerinStudies of NitroglycerinNitroglycerin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Transdermal patches applied to skin 30 minutes before cardiac catheterization

    Also known as: Nitrong tts 10mg- Lavipharm S.A.

  • DrugPlacebo patches

    Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization

06

What researchers measure

Primary outcomes

  1. Radial Spasm occurrence

    Radial spasm is measured by the exerting force (in Newton) removing the sheath from the patient

    Time frame: Immediately after the end of the procedure

  2. Successful radial puncture

    The success is defined by the fast radial puncture and catheterization and is measured by the time of radial catheterization

    Time frame: During radial puncture and catheterization

Secondary outcomes

  1. VRS-4 pain scale

    The pain during the procedure is measured by the four-category verbal rating scale (VRS-4)

    Time frame: During the whole procedure

  2. State-Trait Anxiety Inventory (STAI)

    The anxiety during the procedure is measured by the State - Trait Anxiety Inventory (STAI)

    Time frame: During the whole procedure

07

Study locations

1 of 1 sites recruiting
  • 424 GeneralMH
    Thessaloniki, 56429, Greece
    Recruiting
    • Fotios Oikonomou, MD, PhD · Contacteconomouf@gmail.com · +306977618318
    • Fotios Oikonomou, MD, Phd · Principal investigator
    • Ioannis Doundoulakis, MD · Sub investigator
    • Myrto Samara, MD, PhD · Sub investigator
    • Iliada Kalamakidou, RN · Sub investigator
    • Georgios Papazisis, MD, Phd · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2021, 11 months after the start.

Of 11 phase 3 interventional studies under Spasm, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 12. This study's planned 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2021
First posted
Feb 23, 2021
StartActual
Jan 1, 2021
Primary completionEst.
Dec 31, 2021
CompletionEst.
Jun 30, 2022
Last update
Feb 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04766151
Lead sponsor
424 General Military Hospital
Responsible party
Fotios Oikonomou (Consultant Interventional Cardiologist - Head of Cath Lab, 424 General Military Hospital) — Principal investigator
First posted
Feb 23, 2021
Start date
Jan 1, 2021
Primary completion
Dec 31, 2021 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Feb 23, 2021

Study contacts

Fotios Oikonomou, MD, PhD
Contact
economouf@gmail.com
00306977618318
Ioannis Doundoulakis, MD
Contact
doudougiannis@gmail.com
00306946002830

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion